Please assess the completion status of the following clinical trial:

Trial Title: Combined Biological Treatment and Chemotherapy for Patients With Inoperable Cholangiocarcinoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically verified adenocarcinoma arisen from gallbladder, extra or intrahepatic bile ducts or malignant cells consistent with the above and concomitant radiologic findings consistent with cholangiocarcinoma.~* Curative treatment presently discounted (surgery, stereotactic radiotherapy, etc.)~* KRAS analyzed and found wild-type (wt) or mutated~* PS 0-2~* Evaluable disease according to RECIST criteria, i.e., the disease does not need to be measurable~* Haematology:~  * ANC ≥ 1.5 x 10\^9/l~ * Thrombocytes ≥ 100x10\^9/l~* Biochemistry:~  * Bilirubinaemia ≤ 3 x upper normal value~ * ALAT ≤ 5 x upper normal value~* Creatinin ≤ upper normal value. If raised creatinin, the measured or calculated GFR must be at least 50% of the lower normal value.~* Fertile women must present a negative pregnancy test and use birth control during and 3 months after treatment. The following methods are considered safe birth control: Birth control pills, coil, gestagen deposit injection, subdermal implantation, hormonal vagina ring, and transdermal deposit band-aid)~* Oral and written informed consent~Exclusion Criteria:~* Chemotherapy within 4 weeks~* Radiotherapy within 4 weeks~* Immunotherapy within 4 weeks~* Other concomitant experimental treatment~* Known neuropathy ≥ grade 2~* Serious congruous medical disease~* Other previous malignant disease within 5 years, excl. non-melanoma skin cancer and carcinoma in situ cervicis uteri~* Previous serious and unexpected reactions to fluoropyrimidine treatment~* Hypersensitivity to one or more of the active substances, auxiliary substances or fluoruracil~* Patients with interstitial pneumonitis or pulmonary fibrosis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- KRAS wildtype (Type: OTHER): None
- KRAS mutation (Type: OTHER): Inclusion has been completed in the KRAS mutation arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).